A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 09 01; 30(9):1487-1495.

View in: PubMed

subject areas

Adenocarcinoma
Aged
Antibodies, Monoclonal
Drug-Related Side Effects and Adverse Reactions
Esophageal Neoplasms
Esophagogastric Junction
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Stomach Neoplasms
Treatment Outcome

authors with profiles

Michael R. Gold